Black Diamond Therapeutics Shares Surge 32.14% After $780M Licensing Deal with Servier
Black Diamond Therapeutics (BDTX) has signed a global licensing agreement with Servier for its targeted oncology therapy, BDTX-4933, sparking a 32.14% surge in BDTX shares. The deal grants Servier exclusive rights to develop and commercialize BDTX-4933, a potential best-in-class therapy targeting RAF/RAS mutations in solid tumors, including non-small cell lung cancer (NSCLC).
Under the Deal Terms, Black Diamond will receive:
- $70 million upfront payment
- Up to $710 million in milestone payments
- Tiered royalties on global net sales
The Phase 1 investigational drug is designed to target mutations in RAF and RAS pathways, which are known drivers of aggressive cancers. Servier will lead development and commercialization, aiming to accelerate access to the therapy for cancer patients worldwide.
BDTX-4933 is being evaluated in a first-in-human trial to determine its safety, tolerability, and anti-tumor activity in patients with BRAF, CRAF, and NRAS-mutant cancers. Servier, which invests 70% of its R&D budget into oncology, sees the drug as a key asset in its growing oncology portfolio.
Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics stated: “This agreement supports our mission to advance oral cancer therapies designed to give patients the opportunity for longer, healthier, and more active lives, Servier’s commitment to innovation and deep expertise in oncology make it an ideal partner for Black Diamond as we work to develop breakthrough cancer treatments.”
